BioTissue Technologies AG
BioTissue AG english
BioTissue acquires majority stake in Cell-Lining
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
BioTissue acquires majority stake in Cell-Lining
– BioTissue acquires majority stake in Cell-Lining
– Hardly any impact on BioTissue’s cash balances
– Basis for a sixth product set
Freiburg, August 21, 2002 – BioTissue Technologies AG (SIN 618061) is exercising
its option, concluded on June 28, 2001 to acquire a participation in Cell-
Lining Gesellschaft für Zellkultivierung mbH, Berlin, as at August 15, 2002 and
is taking a majority, 51-percent stake in said company. The acquisition of the
majority holding has hardly any impact on BioTissue Technologies AG cash
balances.
In this way, BioTissue sets the basis to expand its own portfolio to feature a
sixth innovative product. By now taking the project forwards, we are also laying
the foundations for a future industry alliance.
In recent months, BioTissue has further advanced the vessel prosthesis coated
with autologous cells that Cell-Lining developed, thus creating the
preconditions for manufacturing the prosthesis as a medical product. First
clinical use of the vessel prosthesis with patients is scheduled for this year.
An investor has already been found to fund the remaining development work and
the monitoring of the applications.
As of the fourth quarter 2002 Cell-Lining Gesellschaft für Zellkultivierung mbH
will be included in the BioTissue Technologies Group consolidation.
Contact: BioTissue Technologies AG, Rainer Seubert, CFO, Phone: +49-761-7676100,
info@biotissue-tec.com
end of ad-hoc-announcement (c)DGAP 21.08.2002
——————————————————————————–
WKN: 618061; ISIN: DE0006180615; Index:
Listed: Neuer Markt in Frankfurt;
Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und
Stuttgart
210831 Aug 02
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found